Atorvastatin improves microenvironment to enhance the beneficial effects of BMSCS therapy in a rabbit model of acute myocardial infarction

Cellular Physiology and Biochemistry

Volumn 32, Issue 2, 2013, Pages 380-389

  Qu, Zhe ^a   Xu, Hongxin ^a   Tian, Yihao ^a,b   Jiang, Xuejun ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

Acute myocardial infarction; Apoptosis; Atorvastatin; Bone marrow stem cells (BMSCs); Cardiac function; Cell survival; Transplantation

Indexed keywords

ATORVASTATIN; EOSIN; HEMATOXYLIN;

ACUTE HEART INFARCTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW CELL; BONE MARROW DERIVED MESENCHYMAL STROMAL CELL; CARDIOVASCULAR PARAMETERS; CELL DIFFERENTIATION; CELL INFILTRATION; CELL SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORONARY ARTERY LIGATION; ECHOCARDIOGRAPHY; EXPERIMENTAL LIGATION; EXPERIMENTAL MYOCARDIAL INFARCTION; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; LEFT VENTRICULAR FRACTIONAL SHORTENING; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LEFT VENTRICULAR SYSTOLIC PRESSURE; MESENCHYMAL STROMA CELL; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; RABBIT MODEL; SURVIVAL RATE; TUMOR MICROENVIRONMENT;

ORYCTOLAGUS CUNICULUS;

ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOHISTOCHEMISTRY; MESENCHYMAL STEM CELL TRANSPLANTATION; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; PYRROLES; RABBITS;

EID: 84885580970     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000354445     Document Type: Article

References (43)

1. Przybyt E, Harmsen MC: Mesenchymal Stem Cells: promising for myocardial regeneration? Curr Stem Cell Res Ther 2013;270-277.
2. Williams AR, Suncion VY, McCall F, Guerra D, Mather J, Zambrano JP, Heldman AW, Hare JM: Durable scar size reduction due to allogeneic mesenchymal stem cell therapy regulates whole-chamber remodeling. J Am Heart Assoc 2013;2:e000140.
3. Richardson JD, Bertaso AG, Psaltis PJ, Frost L, Carbone A, Paton S, Nelson AJ, Wong DT, Worthley MI, Gronthos S, Zannettino AC, Worthley SG: Impact of timing and dose of mesenchymal stromal cell therapy in a preclinical model of acute myocardial infarction. J Card Fail 2013;19:342-353.
4. Lu M, Zhao S, Liu Q, Jiang S, Song P, Qian H, Zhang Y, Ling J, Yan C, Cheng H, Ma N, Zhao H, Liu Y: Transplantation with autologous mesenchymal stem cells after acute myocardial infarction evaluated by magnetic resonance imaging: an experimental study. J Thorac Imaging 2012;27:125-35.
5. Orlic D, Kajstura J, Chimenti S, Bodine DM, Leri A, Anversa P: Bone marrow stem cells regenerate infarcted myocardium. Pediatr Transplant 2003;7:S86-88.
6. Donndorf P, Strauer BE, Haverich A, Steinhoff G: Stem cell therapy for the treatment of acute myocardial infarction and chronic ischemic heart disease. Curr Pharm Biotechnol 2013;14:12-19.
7. Song H, Kwon K, Lim S, Kang SM, Ko YG, Xu Z, Chung JH, Kim BS, Lee H, Joung B, Park S, Choi D, Jang Y, Chung NS, Yoo KJ, Hwang KC: Transfection of mesenchymal stem cells with the FGF-2 gene improves their survival under hypoxic conditions. Mol Cells 2005;19:402-407.
8. Samper E, Diez-Juan A, Montero JA, Sepúlveda P: Cardiac cell therapy: boosting mesenchymal stem cells effects. Stem Cell Rev 2013;9:266-280.
9. Koudstaal S, Jansen Of Lorkeers SJ, Gaetani R, Gho JM, van Slochteren FJ, Sluijter JP, Doevendans PA, Ellison GM, Chamuleau SA. Concise review: Heart regeneration and the role of cardiac stem cells. Stem Cells Transl Med 2013; 2013;2:434-443.
10. Hsiao LC, Carr C, Chang KC, Lin SZ, Clarke K. Review Article: Stem Cell-based Therapy for Ischemic Heart Disease. Cell Transplant 2013;22:663-675.
11. Haider KH, Ashraf M: Preconditioning approach in stem cell therapy for the treatment of infarcted heart. Prog Mol Biol Transl Sci 2012;111:323-356.
12. Clifford DM, Fisher SA, Brunskill SJ, Doree C, Mathur A, Watt S, Martin-Rendon E: Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev 2012;2:CD006536. doi: 10.1002/14651858. CD006536.pub3.
13. Dauwe DF, Janssens SP: Stem cell therapy for the treatment of myocardial infarction. Curr Pharm Des 2011;17:3328-3340.
14. Dai W, Kloner RA: Bone marrow-derived cell transplantation therapy for myocardial infarction: lessons learned and future questions. Am J Transplant 2011;11:2297-2301.
15. Yang YJ, Qian HY, Huang J, Geng YJ, Gao RL, Dou KF, Yang GS, Li JJ, Shen R, He ZX, Lu MJ, Zhao SH: Atorvastatin treatment improves survival and effects of implanted mesenchymal stem cells in post-infarct swine hearts. Eur Heart J 2008;29:1578-1590.
16. Cai A, Zheng D, Dong Y, Qiu R, Huang Y, Song Y, Jiang Z, Rao S, Liao X, Kuang J, Dai G, Mai W: Efficacy of Atorvastatin combined with adipose-derived mesenchymal stem cell transplantation on cardiac function in rats with acute myocardial infarction. Acta Biochim Biophys Sin (Shanghai) 2011;43:857-866.
17. Wang A, Shen F, Liang Y, Wang J: Marrow-derived MSCs and atorvastatin improve cardiac function in rat model of AMI. Int J Cardiol 2011;150:28-32.
18. Dong Q, Yang Y, Song L, Qian H, Xu Z: Atorvastatin prevents mesenchymal stem cells from hypoxia and serum-free injury through activating AMP-activated protein kinase. Int J Cardiol 2011;153:311-316.
19. Post S, Post MC, van den Branden BJ, Eefting FD, Goumans MJ, Stella PR, van Es HW, Wildbergh TX, Rensing BJ, Doevendans PA: Early statin treatment prior to primary PCI for acute myocardial infarction: REPERATOR, a randomized placebo-controlled pilot trial. Catheter Cardiovasc Interv 2012;80:756-765.
20. Jazi SM, Esfahani MH, Fesharaki M, Moulavi F, Gharipour M: Initial clinical outcomes of intracoronary infusion of autologous progenitor cells in patients with acute myocardial infarction. ARYA Atheroscler 2012;7:162-167.
21. Zhang M, Methot D, Poppa V, Fujio Y, Walsh K, Murry CE: Cardiomyocyte grafting for cardiac repair: graft cell death and antideath strategies. J Mol Cell Cardiol 2001;33:907-921.
22. Dhein S, Garbade J, Rouabah D, Abraham G, Ungemach FR, Schneider K, Ullmann C, Aupperle H, Gummert JF, Mohr FW: Effects of autologous bone marrow stem cell transplantation on beta-adrenoceptor density and electrical activation pattern in a rabbit model of non-ischemic heart failure. J Cardiothorac Surg 2006;1:17.
23. Ning J, Li C, Li H, Chang J: Bone marrow mesenchymal stem cells differentiate into urothelial cells and the implications for reconstructing urinary bladder mucosa. Cytotechnology 2011;63:531-539.
24. Honczarenko M, Le Y, Swierkowski M, Ghiran I, Glodek AM, Silberstein LE: Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells 2006;24:1030-1041.
25. Flynn A, Chen X, O'Connell E, O'Brien T: A comparison of the efficacy of transplantation of bone marrowderived mesenchymal stem cells and unrestricted somatic stem cells on outcome after acute myocardial infarction. Stem Cell Res Ther 2012;3:36.
26. Yao Y, Zhang F, Wang L, Zhang G, Wang Z, Chen J, Gao X: Lipopolysaccharide preconditioning enhances the efficacy of mesenchymal stem cells transplantation in a rat model of acute myocardial infarction. J Biomed Sci 2009;16:74. doi: 10.1186/1423-0127-16-74.
27. Abbate A, Biondi-Zoccai GG, Van Tassell BW, Baldi A: Cellular preservation therapy in acute myocardial infarction. Am J Physiol Heart Circ Physiol 2009;296:H563-565.
28. Carvalho JL, Braga VB, Melo MB, Campos AC, Oliveira MS, Gomes DA, Ferreira AJ, Santos RA, Goes AM: Priming mesenchymal stem cells boosts stem cell therapy to treat myocardial infarction. J Cell Mol Med 2013;17:617-625.
29. Herrmann JL, Abarbanell AM, Wang Y, Weil BR, Poynter JA, Manukyan MC, Meldrum DR: Transforming growth factor-α enhances stem cell-mediated postischemic myocardial protection. Ann Thorac Surg 2011;92:1719-1725.
30. Wang L, Pasha Z, Wang S, Li N, Feng Y, Lu G, Millard RW, Ashraf M: Protein kinase G1 α overexpression increases stem cell survival and cardiac function after myocardial infarction. PLoS One 2013;8:e60087.
31. Huang F, Zhu X, Hu XQ, Fang ZF, Tang L, Lu XL, Zhou SH: Mesenchymal stem cells modified with miR-126 release angiogenic factors and activate Notch ligand Delta-like-4, enhancing ischemic angiogenesis and cell survival. Int J Mol Med 2013;21:484-492.
32. Miettinen JA, Salonen RJ, Ylitalo K, Niemelä M, Kervinen K, Säily M, Koistinen P, Savolainen ER, Mäkikallio TH, Huikuri HV, Lehenkari P: The effect of bone marrow microenvironment on the functional properties of the therapeutic bone marrow-derived cells in patients with acute myocardial infarction. J Transl Med 2012;10:66. doi: 10.1186/1479-5876-10-66.
33. Gao M, Yang J, Liu G, Wei R, Zhang L, Wang H, Wang G, Gao H, Chen G, Hong T: Ghrelin promotes the differentiation of human embryonic stem cells in infarcted cardiac microenvironment. Peptides 2012;34:373-379.
34. Li TS, Cheng K, Lee ST, Matsushita S, Davis D, Malliaras K, Zhang Y, Matsushita N, Smith RR, Marbán E: Cardiospheres recapitulate a niche-like microenvironment rich in stemness and cell-matrix interactions, rationalizing their enhanced functional potency for myocardial repair. Stem Cells 2010;28:2088-2098.
35. Rameshwar P: Microenvironment at tissue injury, a key focus for efficient stem cell therapy: A discussion of mesenchymal stem cells. World J Stem Cells 2009;1:3-7.
36. Alestalo K, Lehtonen S, Yannopoulos F, Mäkelä T, Mäkelä J, Ylitalo K, Väisänen T, Juvonen T, Anttila V, Sequeiros RB, Lappi-Blanco E, Lehenkari P: Activity of mesenchymal stem cells in a nonperfused cardiac explant model. Tissue Eng Part A 2013;19:1122-1131.
37. Massollo M, Podestà M, Marini C, Morbelli S, Cassanelli C, Pinto V, Ubezio G, Curti G, Uccelli A, Frassoni F, Sambuceti G: Contact with the bone marrow microenvironment readdresses the fate of transplanted hematopoietic stem cells. Exp Hematol 2010;38:968-977.
38. Chen YR, Li Y, Chen L, Yang XC, Su PX, Cai J: The infarcted cardiac microenvironment cannot selectively promote embryonic stem cell differentiation into cardiomyocytes. Cardiovasc Pathol 2011;20:77-83.
39. Rameshwar P, Qiu H, Vatner SF: Stem cells in cardiac repair in an inflammatory microenvironment. Minerva Cardioangiol 2010;58:127-46.3
40. Weng TC, Yang YH, Lin SJ, Tai SH: A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther 2010;35:139-151.
41. McKenney JM: Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review. Postgrad Med 2012;124:7-20.
42. Lipinski MJ, Cauthen CA, Biondi-Zoccai GG, Abbate A, Vrtovec B, Khan BV, Vetrovec GW: Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure. Am J Cardiol 2009;104:1708-1716.
43. Horwich TB, MacLellan WR: Atorvastatin and statins in the treatment of heart failure. Expert Opin Pharmacother 2007;8:3061-3068.